Drug Profile
Research programme: allosteric modulators - Addex Therapeutics
Alternative Names: A2A PAM; ADX 68692; ADX-71743; ADX-71943; ADX-92639; Cpd 23; FSH NAM; FSHR/LHR NAM for sex hormone dependent tumours and reproductive system disorders - Addex Therapeutics; GABA-BR PAM for overactive bladder - Addex; GABABPAMs; IL1R1 NAM (CD121a); mGlu2 NAM; mGlu3 PAM; mGlu4 PAM; mGlu7 NAM; mGluR2 NAM; mGluR3 NAM; mGluR3 PAM; mGluR7 NAM; Orexin 2R NAM; TNFR1 NAM (CD120a); TNFR1 NAM (TNF receptor superfamily); TrkB PAM (RTK superfamily) - Addex Therapeutics; TrkB receptor agonists - Addex; TrkB receptor modulators - Addex; TrkBPAMLatest Information Update: 28 Dec 2023
Price :
$50
*
At a glance
- Originator Addex Pharmaceuticals
- Developer Addex Pharmaceuticals; Addex Therapeutics
- Class Analgesics; Anti-inflammatories; Antidementias; Antidepressants; Antigouts; Antineoplastics; Antiparkinsonians; Antipsoriatics; Antirheumatics; Anxiolytics; Behavioural disorder therapies; Drug withdrawal therapies; Neuroprotectants; Neuropsychotherapeutics; Nootropics; Osteoporosis therapies; Sleep disorder therapies; Small molecules; Urologics
- Mechanism of Action Adenosine A2 receptor modulators; Chorionic gonadotropin modulators; Follicle stimulating hormone modulators; GABA B receptor agonists; Interleukin 2 receptor modulators; Luteinising hormone modulators; Metabotropic glutamate receptor 2 modulators; Metabotropic glutamate receptor 7 modulators; Metabotropic glutamate receptor modulators; Orexin receptor type 2 modulators; Ovarian follicle modulators; TrkB receptor agonists; TrkB receptor modulators; Tumour necrosis factor receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Alzheimer's disease; Amyotrophic lateral sclerosis; Anxiety disorders; Autistic disorder; Charcot-Marie-Tooth disease; Cognition disorders; Endometriosis; Fragile X syndrome; Huntington's disease; Major depressive disorder; Neurodegenerative disorders; Pain; Parkinson's disease; Polycystic ovary syndrome; Post-traumatic stress disorders; Substance-related disorders; Urinary incontinence; Visceral pain
- Discontinued Gastro-oesophageal reflux; Gout; Inflammatory bowel diseases; Osteoarthritis; Osteoporosis; Pregnancy; Prostate cancer; Psoriasis; Rheumatoid arthritis; Sleep disorders
Most Recent Events
- 28 Dec 2023 No recent reports of development identified for preclinical development in Alzheimer's-disease in Switzerland (PO)
- 28 Dec 2023 No recent reports of development identified for preclinical development in Charcot-Marie-Tooth-disease in Germany (PO)
- 28 Dec 2023 No recent reports of development identified for preclinical development in Charcot-Marie-Tooth-disease in Netherlands (PO)